retatrutide phase 2 trial type 2 diabetes weight loss 2024 2: and Key Findings – Bolt Pharmacy Retatrutide Where to Get: Can

These medications can be life-changing for some individuals, physically and psychologically

Li F, Morgan KL, Zaslavsky AM

Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, not purely a GLP-1 agent

Summary: Injection site selection matters for GLP-1 medications to prevent tissue damage and ensure comfort, though all approved sites deliver equivalent medication exposure

A lower 4mg weekly dose also resulted in impressive weight loss results, with an average loss of 17% over 48 weeks and: 92% of participants lost at least 5% of their starting body weight 75% lost at least 10% of their body weight 60% lost at least 15% of their starting weight Retatrutide vs Mounjaro In clinical trials, the active ingredient in Mounjaro, tirzepatide, results in an average weight loss of 22.5% at the highest 15mg per week dose over 72 weeks